Vimarsana
Biggest News Aggregation in the World

Available Methods News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Available Methods. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Available Methods Today - Breaking & Trending Today

TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial - Vimarsana News

TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

Published: June 2, 2024

WILMINGTON, Del.--(BUSINESS WIRE)--Jun 2, 2024--

Source: joplinglobe.com
Related Topics:
United StatesUnited KingdomChelsea TresslerDaiichi SankyoBrendan McevoyAmerican Society Of Clinical OncologyWorld Health OrganizationLungevity FoundationLung Ambition AllianceInternational Agency For Research On CancerArchives Pathology LabSingle Institution StudyPlenary SessionClinical OncologyAnnual MeetingNew England JournalPrescription InformationPatient InformationSouth AmericaRare DiseasesInternational AgencyLung FactAccessed MayCancer BiomarkersPresent Status
TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial - Vimarsana News

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

Published: February 19, 2024

First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting ...

Source: marketscreener.com
Related Topics:
United StatesUnited KingdomSuresh RamalingamSusan GalbraithCerner CancermpactDaiichi SankyoInternational Agency For Research On CancerAmerican Cancer SocietyLung Ambition AllianceWinship Cancer Institute Of Emory UniversityLungevity FoundationSingle Institution StudyWorld Health OrganisationExecutive DirectorWinship Cancer InstituteEmory UniversityExecutive Vice PresidentPrescription InformationPatient InformationSouth AmericaRare DiseasesInternational AgencyLung FactAccessed FebruaryWhat Is Lung
Complying with the Children's Online Privacy Protection Rule; FTC's Proposed Updates | Kilpatrick - Vimarsana News

Complying with the Children's Online Privacy Protection Rule; FTC's Proposed Updates | Kilpatrick

Published: January 17, 2024

On December 20, 2023, the Federal Trade Commission (FTC) published a Notice of Proposed Rulemaking (Proposed Rule) seeking to update the Children’s Online Privacy Protection Act...

Source: jdsupra.com
Related Topics:
School For Educational ServicesSchool AuthorizationFederal Trade CommissionProposed RulemakingProposed RuleOnline Privacy Protection ActAudience SitesDirected Standard ChangesPersonal InformationThird PartiesAvailable MethodsObtaining Opt In ConsentEducational ServicesAuthorized Education PurposeSecurity RequirementsDeletion RequirementsOperations ExceptionContact ExceptionOnline Privacy Protection Rule
TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer - Vimarsana News

TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer

Published: October 16, 2023

WILMINGTON, Del.--(BUSINESS WIRE)--Oct 16, 2023--

Source: eagletribune.com
Related Topics:
United KingdomUnited StatesSusan GalbraithBrendan McevoyDaiichi SankyoChelsea FordWorld Health OrganisationInternational Agency For Research On CancerLungevity FoundationSingle Institution StudyLung Ambition AllianceDrug AdministrationNew Drug ApplicationPriority ReviewPrescription Drug User Fee ActExecutive Vice PresidentPresidential SymposiumInternational AssociationLung CancerPrescription InformationPatient InformationSouth AmericaRare DiseasesAccessed SeptemberInternational Agency
TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial - Vimarsana News

TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial

Published: September 11, 2023

Combination reduced the risk of disease progression by 38% versus TAGRISSO monotherapy, the current 1st-line global standard of care ...

Source: marketscreener.com
Related Topics:
United KingdomUnited StatesDaiichi SankyoSingle Institution StudyLung Ambition AllianceCompany On Social Media AstrazenecaLungevity FoundationWorld Health OrganisationInternational Agency For Research On CancerPresidential SymposiumInternational AssociationLung CancerPrescribing InformationPatient InformationSouth AmericaRare DiseasesSocial MediaInternational AgencyLung FactAccessed AugustSmall CellHistological SamplesNon Small Cell Lung CancerSystematic ReviewIntj Clin Exp